Multicellular living organisms and unmodified parts thereof and – Nonhuman animal – Transgenic nonhuman animal
Reexamination Certificate
1997-09-05
2001-03-20
Crouch, Deborah (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Nonhuman animal
Transgenic nonhuman animal
C800S004000, C800S006000, C800S015000, C800S016000, C800S017000, C800S018000, C800S025000
Reexamination Certificate
active
06204431
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Technical Field
The subject invention relates to methods of producing non-human transgenic mammals which produce various oligosaccharides in their milk. Additionally, the subject invention relates to the generated mammals, the milk which these mammals produce, compositions comprising the milk, fractions of the milk, and the purified oligosaccharides, as well as glycoproteins, present in the milk.
2. Background Information
In the past, several individuals have achieved transgenic expression of primary gene products (i.e., proteins) in the milk of transgenic mammals (U.S. Pat. No. 5,322,775, Wall et al.,
Proc. Natl. Acad. Sci. USA
88:1696-1700 (1991) and Krimpenfort, P.,
Cancer Detection and Prevention
17(2):301-305 (1993)). Such expression was carried out in order to produce large quantities of the heterologous proteins in milk (Velander et al.,
Scientific American,
January 1997, pp.70-74).
Recently, it was also demonstrated that expression of secondary transgenic products, for example, oligosaccharides, glycoproteins and glycolipids is, in fact, possible (Prieto et al.,
Journal of Biological Chemistry
49:29515-29519 (1995)). The experiments carried out by Prieto et al. advanced the concept of using the mammary glands of transgenic mammals as bioreactors and not solely as an alternative protein synthesis system.
Most of the experiments referenced in the above articles were carried out by expression of heterologous transgenes. One reason for such expression is because homologous genes, which are transgenically expressed, may cause difficulties, due to conflicts with internal protein synthesis of mammary gland development (Burdon et al.,
Mechanisms of Development
36:64-67 (1991)). Another reason why heterologous transgenes are utilized is that most of the experiments which have been carried out are designed for the production of human biological products.
The synthesis of secondary gene products, such as milk oligosaccharides, depends primarily on the expression of glycosyltransferases during lactation. Additionally, there are many benefits to the production of such oligosaccharides. For example, in a transgenic system for the synthesis of oligosaccharides, only catalytic amounts of glycosyltransferases are necessary. Also, the origin of the transgene may not be relevant as long as the secondary gene product or products are the desired one or ones.
It must also be noted that non-human mammals have a variety of glycosyltransferases which have counterparts in the human enzyme repertoire (Thurin et al.,
The Journal of Biological Chemistry
265(12):7055-7061 (1990)). Some of these transferases have been cloned from the tissues of non-human mammals, for example, mice (Larsen et al.,
Proc. Natl. Acad. Sci. USA
86:8227-8231 (1989)). Thus, transgenic expression of homologous glycosyltransferases in the mammary glands of non-human mammals represents a means of producing oligosaccharides, in addition to oligosaccharides produced using heterologous glycosyltransferases. Expression of both such enzyme types, as well as the oligosaccharides which are created by the action of such enzymes, and glycoproteins related thereto, are considered to fall within the scope of the present invention.
The oligosaccharides described above may be added, for example, to infant formula so that the formula-fed infant may receive the same benefits as the breast fed infant. For example, it is possible that the oligosaccharides may provide resistance to infection by pathogenic bacteria (Prieto et al., supra). Additionally, such oligosaccharides may be added to other compositions such as nutritional supplements or to pharmaceuticals. The aim of the present invention is to produce non-human transgenic mammals which produce such oligosaccharides, using either homologous or heterologous enzymes including, for example, glycosyltransferases. Such oligosaccharides may then be added to various compositions due to their beneficial properties.
Additionally, the presence of oligosaccharides and other glycoconjugates in the milk of transgenic animals may result in the acquisition of protection or resistance to viral, bacterial or fungal infections or toxins, by the offspring of such animals.
SUMMARY OF THE INVENTION
The present invention encompasses a method of synthesizing oligosaccharides and glycoproteins through transgenic expression of enzymes, for example, glycosyltransferases, during lactation. Furthermore, the invention also includes the production of oligosaccharide structures which are not present in nature. Such structures may be produced by transgenically expressing the appropriate eukaryotic or prokaryotic enzyme of interest, for example, a glycosyltransferase, in a mammal. Thus, the present invention allows for the production of homologous, heterologous and novel structures in the milk of transgenic mammals.
More specifically, the present invention encompasses a method for producing a non-human, transgenic mammal whose somatic and germ cells contain at least one transgene. Expression of the transgene results in the production of oligosaccharides and glycoproteins in the milk of the mammal. The method comprises the steps of: (a) preparing at least one transgene, (b) introducing the transgene or transgenes into a non-human, mammalian embryo, and transferring the resulting embryo into a recipient female, and then (c) identifying at least one female offspring. Expression of the transgene or transgenes results in the production of at least one enzyme which then catalyzes the production of oligosaccharides and glycoproteins in the milk of the mammal. Each transgene itself comprises, in operable association, at least one expression regulatory sequence functional in mammary secretory cells, a DNA sequence encoding a signal sequence functional in mammary secretory cells, and a DNA sequence encoding an enzyme. The non-human, transgenic mammal may be, for example, a mouse, a rat, a rabbit, a pig, a goat a sheep or a cow. The enzyme may be, for example, a glycosyltransferase such as a fucosyltransferase, a galactosyltransferase, an acetylase, a glucoronyltransferase, a gluconylepimerase, a sialyltransferase, a mannosyltransferase, a sulfotransferase, a &bgr;-acetylgalactosaminyltransferase or a N-acetylglucosaminyltransferase. Additionally, the oligosaccharides may be, for example, galactose &agr;1-3 galactose &bgr;1-4 glucose, 2′fucosyllactose, 3′fucosyllactose, lacto-N-neo-tetraose, lacto-N-tetraose, lacto-N-fucopentaose, a sialylated derivative of lacto-N-fucopentaose, lacto-N-fucopentaose II, a sialylated derivative of lacto-N-fucopentaose II, lacto-N-fucopentaose III, a sialylated derivative of lacto-N-fucopentaose III, lacto-N-fucopentaose IV, a sialylated derivative of lacto-N-fucopentaose IV, lacto-N-fucopentaose V, a sialylated derivative of lacto-N-fucopentaose V, lacto-N-di-fucopentaose I, a sialylated derivative of lacto-N-di-fucopentaose, lacto-N-di-fucopentaose II, a sialylated derivative of lacto-N-di-fucopentaose II, lacto-N-hexaose, a fucosylated derivative of lacto-N-hexaose, sialyltetrasaccharide a, a fucosylated derivative of sialyltetrasaccharide a, sialyltetrasaccharide b, a fucosylated derivation of sialyltetrasaccharide b, sialyltetrasaccharide c or a fucosylated derivative of sialyltetrasaccharide c.
Additionally, the present invention includes a non-human, transgenic mammal. The genome of the mammal comprises at least one DNA sequence encoding an enzyme operatively linked to a mammary gland-specific promoter. Expression of the DNA sequence or sequences results in the production of oligosaccharides and glycoproteins in the milk of the mammal. The mammal, enzyme and oligosaccharides may be those recited above.
Furthermore, the present invention includes a method of producing milk in a non-human, transgenic mammal. The method includes (a) preparing at least one transgene, (b) inserting the transgene or transgenes into the non-human, transgenic mammal, and (c) milking the non-human, transgenic mammal in order to obtain the milk. The milk comprise
Cummings Richard D.
Kopchick John J.
Moremen Kelley W.
Pierce James M.
Prieto Pedro A.
Abbott Laboratories
Becker Cheryl L.
Crouch Deborah
LandOfFree
Transgenic non-human mammals expressing heterologous... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transgenic non-human mammals expressing heterologous..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenic non-human mammals expressing heterologous... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2537317